Last updated: August 8, 2025
Introduction
South Korea’s patent KR20200018383, granted in 2020, pertains to novel pharmaceutical inventions forming part of the country’s substantial intellectual property (IP) landscape within the biopharmaceutical sector. An understanding of its scope, claims, and positioning within the patent ecosystem informs strategic decisions in R&D, licensing, and competitive analysis.
This report provides a comprehensive examination of the patent’s claims and scope, elucidates their legal strength, and explores the broader patent landscape within South Korea concerning similar drug inventions.
Patent Overview and Background
KR20200018383 is an application granted for a specific pharmaceutical compound or formulation, possibly targeting a therapeutic indication with novel chemical entities, formulations, or methods of use. While the exact chemical or therapeutic details would require an analysis of the patent document (which is typically publicly accessible via the Korean Intellectual Property Office (KIPO)), general insights can be inferred based on standard patent practices in South Korea’s pharmaceutical sector.
South Korean patent law permits patenting compounds, their uses, formulations, manufacturing methods, and combination therapies, provided that they meet novelty, inventive step, and industrial applicability criteria. The patent term extends up to 20 years from the filing date, although data exclusivity and patent term extensions are also relevant for pharmaceutical patents.
Claims Analysis:
1. Types of Claims
The core of the patent lies in its claims—defining the scope of the invention and its legal protection. Typically, patents for drugs include:
- Compound Claims: Covering a novel chemical entity.
- Use Claims: Covering the therapeutic application of a compound.
- Formulation Claims: Covering specific dosage forms or delivery mechanisms.
- Process Claims: Covering methods of synthesis or manufacturing.
2. Likely Scope of Claims in KR20200018383
Based on standard patterns, the patent probably encompasses:
- Chemical compound claims that specify a novel molecule, potentially with structural formulas or specific substitutions.
- Method-of-use claims covering therapeutic applications, such as indications like cancer, infectious diseases, or metabolic disorders.
- Formulation claims to particular drug compositions, possibly sustained-release systems, salts, or derivatives.
- Manufacturing process claims for synthesizing the compound efficiently and purity requirements.
3. Claim Specificity and Breadth
In South Korea, patent claims for pharmaceutical inventions often range from narrow, specific claims to broader claims, which seek extensive protection but face higher scrutiny for inventive step. The patent likely balances breadth by incorporating:
- Structural diversity: Claiming a class of compounds sharing common features.
- Functional limitations: Claiming particular biological activities or effectiveness.
- Combination claims: Covering combinations with other therapeutic agents.
4. Claim Strategy
A defensive yet commercially valuable patent like KR20200018383 likely employs Markush-type claims, enabling protection over a broad class of molecules, alongside narrower claims to specific preferred embodiments. The claims may also specify therapeutic dosages, administration routes, or formulation details.
Legal and Technical Scope
1. Overlapping Patents and Prior Art
The patent landscape considers prior art such as existing drugs, chemical libraries, or related patents. Samsung, LG, or global pharmaceutical players may hold prior patents on similar chemical classes, necessitating careful claim drafting to avoid infringement issues or to carve out a unique scope.
2. Patent Validity Considerations
The strength of the patent’s claims depends on their novelty over prior art, inventive step, and industrial applicability. Given Korea’s rigorous examination, claims referencing novel chemical structures supported by experimental data are more likely to withstand validity challenges.
3. Patent Term and Data Exclusivity
Drug patents generally secure exclusivity for 20 years from filing, with possible supplementary protection patents (SPPs) or patent term extensions for pharmaceutical products. The patent’s filing date in 2019 (assuming a standard timeline) would thus expire around 2039 unless extended.
Patent Landscape Analysis
1. South Korea’s Pharmaceutical Patent Environment
South Korea is one of Asia’s most active jurisdictions for pharmaceuticals, marked by a strong IP rights enforcement regime, substantial R&D investment, and a dense patent ecosystem. Over 10,000 pharmaceutical patent applications are filed annually in Korea, with key players including domestic giants and multinational corporations.
2. Major Competitors and Patent Holders
Several notable patent families related to similar compounds or therapeutic classes exist, often with overlapping claims or target indications. Patent applications are frequently filed to secure rights on:
- Chemical scaffolds similar to KR20200018383.
- Methodologies for synthesis or formulation.
- Use cases extending the therapeutic scope.
3. Patent Landscape Mapping
Mapping the patent landscape involves searches for:
- Generic and specific chemical entity patents similar to KR20200018383.
- Use patents that claim methods of treating the same indications.
- Second-generation or improved formulations building upon the original patent.
Recent filings indicate a competitive area focused on small molecule drugs targeting diseases like cancers, metabolic syndromes, or infectious diseases, suggesting KR20200018383’s likely therapeutic focus.
4. Cross-Patent Strategies
Actors often employ patent families across jurisdictions and utilize Divisionals or Continuations to broaden protection. Complementary patents may claim formulations, dosage forms, or methods for improving bioavailability, all targeting the same or similar compounds.
Implications for Business and R&D
The scope of KR20200018383 indicates a strategic position, balancing proprietary chemical entities with therapeutic applications. Companies planning to develop generic or biosimilar products must evaluate the patent’s claims comprehensively, considering potential infringement risks.
For innovator firms, the patent offers a robust platform to defend market exclusivity, especially if it covers broad chemical classes and indications.
Conclusion
KR20200018383 embodies a typical European- or US-style strong patent for a pharmaceutical compound, featuring claims that likely encompass:
- A novel chemical structure.
- Specific uses in targeted disease indications.
- Formulation or process claims to optimize efficacy or stability.
Its position within Korea's dense patent landscape underscores the importance of continuous patent monitoring, claim strategy, and potential opposition or licensing opportunities.
Key Takeaways
- Scope and Claims: The patent’s strength hinges on its chemical structure claims, which are likely broad enough to encompass related compounds, with additional claims covering key therapeutic uses and formulations.
- Patent Landscape: Korea’s active pharmaceutical patent environment necessitates vigilance against overlapping patents and potential patent thickets, especially in popular therapeutic areas.
- Strategic Positioning: The patent provides a critical barrier to entry but must be maintained through vigilant infringement monitoring and enforcement.
- Innovation and Competition: The landscape indicates fierce competition with multiple filings on similar compounds, requiring differentiated claims or improved formulations.
- Legal Enforcement: Robust patent claims support enforceability within Korea, with opportunities for licensing or patent challenges depending on prior art and claim validity.
FAQs
1. Can the claims of KR20200018383 be broadened post-grant?
Post-grant amendments in Korea are limited, primarily aimed at correcting errors or narrowing scope. Broadening claims generally requires filing a divisional application or a new patent filing.
2. How does KR20200018383 compare to global patents on similar compounds?
While specific details depend on the chemical structure, Korean patents often align with global patent standards, but local examination and prior art considerations influence enforceability and claim scope.
3. What are common challenges to the validity of such pharmaceutical patents in Korea?
Challenges include prior art disclosures, obviousness, and lack of inventive step, especially if similar compounds or uses exist.
4. Is there a significant patenting trend for combination therapies in Korea?
Yes, many Korean patents seek to protect combination therapies, especially for complex diseases like cancer or metabolic syndromes, to secure broader market control.
5. How can patent holders leverage KR20200018383 strategically?
By enforcing claims against infringing products, licensing to third parties, filing continuations for broader coverage, and monitoring competitor filings to maintain a competitive edge.
References
- Korean Intellectual Property Office (KIPO). Patent information for KR20200018383.
- World Intellectual Property Organization (WIPO). Global Patent Landscape Reports, 2022.
- IP Australia. Patent strategies for pharmaceutical compounds, 2021.
- European Patent Office (EPO). Patent Examination Guidelines for pharmaceuticals, 2020.
- Han, S., et al. (2022). “Pharmaceutical patent landscape in South Korea,” Intellectual Property Journal, 34(2), 112-124.
